GFOGER peptide
Based on 1 Customer Validation
GFOGER peptide is an artificially synthesized collagen-mimetic sequence. GFOGER peptide acts as a ligand for α2β1, α11β1 and α1β1 integrins, thereby supporting integrin-mediated cell adhesion to collagen. GFOGER peptide triggers signaling pathways mediated by the α2β1 integrin receptor and upregulates osteoblast differentiation. GFOGER peptide accelerates and enhances bone formation at sites of refractory femoral defects. GFOGER peptide can be passively adsorbed onto polymer scaffolds for cell-free/growth factor-free bone formation. GFOGER peptide is used in biomaterials such as hydrogels and 3D bioinks for tissue engineering research including bone formation.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- Reinheit: 99.53%
- CAS. Nr.: 245120-10-9
- Formel: C29H43N9O10
- Molecular Weight:677.71
-
Speicherung:
Sealed storage, away from moisture.
Powder -80°C, 2 years , -20°C, 1 year* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biologische Aktivität
-
Chemical Information
-
Lösungsmittel & Löslichkeit
- Reinheit & Dokumentation
- Verweise
-
Help & FAQs
-
Immunology/Inflammation Compound Library
HY-L007
-
Cytoskeleton Compound Library
HY-L060
-
Peptide Library
HY-L105
-
Osteogenesis Compound Library
HY-L131
-
Coagulation and Anti-coagulation Compound Library
HY-L136
-
Membrane Protein-targeted Compound Library
HY-L149
-
Extracellular Vesicles (EVs) Compound Library
HY-L168
-
Multi-Target Compound Library
HY-L176
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Peptide Compound Library
HY-L105S
-
Bioactive Compound Library
HY-L001
-
High-Throughput Bioactive Compound Library
HY-L205
Biologische Aktivität
|
α1β1 |
α2β1 |
GFOGER peptide (20 μg/mL; overnight at 4°C coating, 1 h binding) is bound with high affinity by recombinant human integrin α11 I domain in a Mg2+-dependent solid-phase binding assay[2].
GFOGER peptide (500 μM; 8-10 days, 24 h, 72 h) inhibits 4 mM Pi-induced calcification in MOVAS-1 cells by 66%, does not reduce cell viability, normalizes Pi-induced upregulation of osteogenic marker genes (Runx2, MGP, OCN, TNAP) after 8 days, and normalizes SMPD3 gene expression after 8 days of treatment[3].
GFOGER peptide (500 μM; 14 days) inhibits 4 mM Pi-induced calcification in primary human VSMCs by 58%[3].
GFOGER peptide (500 μM; 10 days) modifies the protein content of 4 mM Pi-treated MOVAS-1 cell-derived EVs, normalizing the expression of most Pi-altered proteins involved in vascular calcification[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Lewis rats (female, 13 to 15 weeks old)[1]
-
Dosage:50 μg/mL (coating concentration); ~260 ng per 9 mm scaffold
-
Administration:implantation; single application
-
Result:Showed radiodense tissue formation as early as 4 weeks post-implantation.
Achieved nearly full defect bridging by 12 weeks post-implantation.
Demonstrated significantly greater bone volume compared to controls at 4 and 12 weeks.
Exhibited bridging scores shifted towards fully bridged or nearly fully bridged (scores 4 and 5) compared to uncoated controls.
Significantly enhanced bone formation compared to uncoated scaffolds when scaffold surface area to volume (SA/V) ratio was at least 3.1 mm-1.
Showed no significant effect on bone formation at SA/V ratios of 2.4 or 1.7 mm-1.
Showed no significant difference in maximum torsional strength, stiffness, and work to failure compared to uncoated scaffold groups.
Chemical Information
-
CAS. Nr. 245120-10-9
-
Appearance Solid
-
Molecular Weight 677.71
-
Formel C29H43N9O10
-
Color White to off-white
-
Sequence
Gly-Phe-{Hyp}-Gly-Glu-Arg
-
Sequence Shortening
GF-{Hyp}-GER
-
Versand
Room temperature in continental US; may vary elsewhere.
-
Speicherung
Sealed storage, away from moisture
Powder -80°C 2 years -20°C 1 year * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Lösungsmittel & Löslichkeit
DMSO : 100 mg/mL (147.56 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)
Reinheit & Dokumentation
-
Data Sheet (280 KB)
-
SDS (254 KB)
- English - EN (254 KB)
- Français - FR (254 KB)
- Deutsch - DE (254 KB)
- Norwegian - NO (254 KB)
- Español - ES (254 KB)
- Swedish - SV (254 KB)
- Italian - IT (254 KB)
- Korean - KR (254 KB)
- Portuguese - PT (254 KB)
-
Handling Instructions (2659 KB)
Verweise
[1]. Wojtowicz AM, et al. Coating of biomaterial scaffolds with the collagen-mimetic peptide GFOGER for bone defect repair. Biomaterials. 2010;31(9):2574-2582. [Content Brief]
[2]. Zhang WM, et al. alpha 11beta 1 integrin recognizes the GFOGER sequence in interstitial collagens. J Biol Chem. 2003 Feb 28;278(9):7270-7. [Content Brief]
[3]. Mansour A, et al. GFOGER Peptide Modifies the Protein Content of Extracellular Vesicles and Inhibits Vascular Calcification. Front Cell Dev Biol. 2020;8:589761. Published 2020 Nov 30. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.4756 mL | 7.3778 mL | 14.7556 mL | 36.8889 mL |
| 5 mM | 0.2951 mL | 1.4756 mL | 2.9511 mL | 7.3778 mL | |
| 10 mM | 0.1476 mL | 0.7378 mL | 1.4756 mL | 3.6889 mL | |
| 15 mM | 0.0984 mL | 0.4919 mL | 0.9837 mL | 2.4593 mL | |
| 20 mM | 0.0738 mL | 0.3689 mL | 0.7378 mL | 1.8444 mL | |
| 25 mM | 0.0590 mL | 0.2951 mL | 0.5902 mL | 1.4756 mL | |
| 30 mM | 0.0492 mL | 0.2459 mL | 0.4919 mL | 1.2296 mL | |
| 40 mM | 0.0369 mL | 0.1844 mL | 0.3689 mL | 0.9222 mL | |
| 50 mM | 0.0295 mL | 0.1476 mL | 0.2951 mL | 0.7378 mL | |
| 60 mM | 0.0246 mL | 0.1230 mL | 0.2459 mL | 0.6148 mL | |
| 80 mM | 0.0184 mL | 0.0922 mL | 0.1844 mL | 0.4611 mL | |
| 100 mM | 0.0148 mL | 0.0738 mL | 0.1476 mL | 0.3689 mL |
GFOGER peptide Related Classifications
HY-P11328 Related Classifications
Powered by Bioz